1. Home
  2. VCIC vs ADCT Comparison

VCIC vs ADCT Comparison

Compare VCIC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VCIC
  • ADCT
  • Stock Information
  • Founded
  • VCIC 2024
  • ADCT 2011
  • Country
  • VCIC United States
  • ADCT Switzerland
  • Employees
  • VCIC N/A
  • ADCT N/A
  • Industry
  • VCIC
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • VCIC
  • ADCT Health Care
  • Exchange
  • VCIC NYSE
  • ADCT Nasdaq
  • Market Cap
  • VCIC 293.0M
  • ADCT 224.3M
  • IPO Year
  • VCIC 2024
  • ADCT 2020
  • Fundamental
  • Price
  • VCIC $10.01
  • ADCT $2.05
  • Analyst Decision
  • VCIC
  • ADCT Strong Buy
  • Analyst Count
  • VCIC 0
  • ADCT 5
  • Target Price
  • VCIC N/A
  • ADCT $8.00
  • AVG Volume (30 Days)
  • VCIC 6.1K
  • ADCT 1.7M
  • Earning Date
  • VCIC 01-01-0001
  • ADCT 11-07-2024
  • Dividend Yield
  • VCIC N/A
  • ADCT N/A
  • EPS Growth
  • VCIC N/A
  • ADCT N/A
  • EPS
  • VCIC N/A
  • ADCT N/A
  • Revenue
  • VCIC N/A
  • ADCT $70,717,000.00
  • Revenue This Year
  • VCIC N/A
  • ADCT $6.58
  • Revenue Next Year
  • VCIC N/A
  • ADCT $11.78
  • P/E Ratio
  • VCIC N/A
  • ADCT N/A
  • Revenue Growth
  • VCIC N/A
  • ADCT N/A
  • 52 Week Low
  • VCIC $9.96
  • ADCT $1.45
  • 52 Week High
  • VCIC $10.20
  • ADCT $6.04
  • Technical
  • Relative Strength Index (RSI)
  • VCIC N/A
  • ADCT 44.05
  • Support Level
  • VCIC N/A
  • ADCT $1.93
  • Resistance Level
  • VCIC N/A
  • ADCT $2.18
  • Average True Range (ATR)
  • VCIC 0.00
  • ADCT 0.40
  • MACD
  • VCIC 0.00
  • ADCT -0.02
  • Stochastic Oscillator
  • VCIC 0.00
  • ADCT 10.65

About VCIC VINE HILL CAP INVT CORP

Vine Hill Capital Investment Corp is a blank check company.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Share on Social Networks: